+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hepatitis B virus immunoglobulin on demand to prevent infection recurrence among liver allograft recipients: report of three cases

Hepatitis B virus immunoglobulin on demand to prevent infection recurrence among liver allograft recipients: report of three cases

Revista Medica de Chile 140(1): 78-83

Infection recurrence rates among hepatitis B virus infected liver allograft recipients, may be as high as 80%. Immunoprophylaxis with anti HBVgammaglobulin may reduce these rates and improve survival. The dose of anti HBV gammaglobulin that must be used is not clearly defined. The most commonly accepted protocol uses 10,000 units during the anhepatic phase and 10,000 units daily during one week, followed by weekly doses of 10,000 units during one month and maintenance with 10,000 units monthly, without measuring anti hepatitis B surface antigen antibodies (antiHBs). Some reports recommend the use of immunoglobulin on demand, to maintain antiHBs titers between 100 and 250 U/l. The infection recurrence rates among patients treated with immunoglobulin and Lamivudine fluctuates between 0 and 10%, during follow up periods of 13 to 30 months. We report three liver allograft recipients that received immunoglobulin on demand, using a mean of 41,000 units, maintaining adequate antiHBs titers.

(PDF emailed within 1 workday: $29.90)

Accession: 053516695

Download citation: RISBibTeXText

PMID: 22552559

Related references

Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. Journal of Gastroenterology and Hepatology 22(12): 2130-2134, 2007

Low-dose hepatitis B immunoglobulin given on demand in combination with lamivudine: A highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77(8): 1203-1208, April 27, 2004

Immunoglobulin M anti-hepatitis C virus core antibodies correlate with hepatitis C recurrence in liver graft recipients. Transplantation Proceedings 28(5): 2966-2969, 1996

A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients. European Journal of Gastroenterology and Hepatology 27(8): 901-906, 2016

Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine. Transplantation Proceedings 37(7): 3187-3189, 2005

Antiviral Combination Therapy With Low-Dose Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Virus Recurrence in Liver Transplant Recipients: A Single-Center Experience. Transplantation Proceedings 47(5): 1445-1449, 2016

Hepatitis C virus infection in liver allograft recipients. Archives of Virology. Supplementum 8: 291-304, 1993

Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. Liver Transplantation and Surgery 3(5): 501-505, 1997

Correlation between risk of hepatitis B virus recurrence and tissue expression of covalently closed circular DNA in living donor liver transplant recipients treated with high-dose hepatitis B immunoglobulin. Transplantation Proceedings 46(10): 3548-3553, 2015

Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. Expert Review of Clinical Immunology 7(4): 429-436, 2011

Long-term application of human polyclonal hepatitis-B immunoglobulin to prevent hepatic allograft infection. A review of the literature and presentation of five cases. Netherlands Journal of Medicine 43(1-2): 74-82, 1993

Reduced doses of hepatitis B immunoglobulin protect against hepatitis B virus infection recurrence after liver transplantation. Transplantation Proceedings 33(4): 2551-2553, 2001

Liver biopsy versus non-invasive parameters for evaluation of liver disease in renal allograft recipients with hepatitis B or C virus infection. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 178A, 2002